Grass Pollen SLIT Slows Course of Allergic Rhinitis, Asthma

This article originally appeared here.
Share this content:
Grass Pollen SLIT Slows Course of Allergic Rhinitis, Asthma
Grass Pollen SLIT Slows Course of Allergic Rhinitis, Asthma

MONDAY, June 5, 2017 (HealthDay News) -- For patients with allergic rhinitis (AR), sublingual immunotherapy (SLIT) is associated with slower AR progression and less frequent asthma onset, according to research published online May 31 in Allergy.

Stefan Zielen, M.D., from the Goethe University Hospital in Frankfurt, Germany, and colleagues examined the real-world, long-term efficiency of grass-pollen SLIT tablets in AR in a retrospective analysis of a longitudinal prescription database. Patients with AR treated with grass pollen SLIT tablets (2,851 patients) were compared with a control group that had not received allergy immunotherapy (AIT; 71,275 patients).

The researchers found that after adjustment for covariates and relative to the pre-treatment period, AR medication use was 18.8 percent lower in the SLIT tablet group versus the non-AIT group (P < 0.001). Compared with the non-AIT group, the onset of asthma was less frequent in the SLIT tablet group (odds ratio, 0.696; P = 0.002), while time to asthma was significantly longer (hazard ratio, 0.523; P = 0.003). Compared with the non-AIT group, the SLIT group had an additional 16.7 percent decrease in asthma medication use after SLIT cessation, relative to the pre-treatment period (P = 0.004).

"Real-world treatment of AR patients with grass pollen SLIT tablets was associated with slower AR progression, less frequent asthma onset, and slower asthma progression," the authors write.

Several authors disclosed financial ties to biopharmaceutical companies, including Stallergenes Greer, which funded the study.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters




More in Home

FDA Approves Palynziq for Phenylketonuria

FDA Approves Palynziq for Phenylketonuria

Drug is a novel enzyme therapy for adult patients with PKU with uncontrolled blood Phe concentrations

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in Tx Candidates With 2017 Hypertension Guidelines

Increase in proportion of adults recommended for treatment; estimated decrease in CVD events, deaths